Gynae BT 2017

BIOLOGIC AGENTS - BEVACIZUMAB Phase II study of Bevacizumab in combination with definitive radiotherapy and cisplatin in locally advanced cervical carcinoma (RTOG 0417)

- 60 patients from 25 institutions were enrolled between 2006 and 2009

- 49 patients evaluable

- Median follow-up time 3.8 years (Mostly IIB 63%, squamous-80% )

- There were 15 (31%) protocol specified treatment-related AEs, most common were

hematologic (12/15 =80

- 3-year OS 81%, DFS 67%, LRF 23%

THÈME DU DIAPORAMA Int J Radiat Oncol Biol Phys 88:101-5; 2014

GUSTAVE ROUSSY